CZ2019997A3 - Deriváty pyridazino [4,5-B] chinolin-5-oxidu, způsob jejich přípravy a jejich použití jako antagonistů glycinu - Google Patents

Deriváty pyridazino [4,5-B] chinolin-5-oxidu, způsob jejich přípravy a jejich použití jako antagonistů glycinu

Info

Publication number
CZ2019997A3
CZ2019997A3 CZ99201A CZ2019997A CZ2019997A3 CZ 2019997 A3 CZ2019997 A3 CZ 2019997A3 CZ 99201 A CZ99201 A CZ 99201A CZ 2019997 A CZ2019997 A CZ 2019997A CZ 2019997 A3 CZ2019997 A3 CZ 2019997A3
Authority
CZ
Czechia
Prior art keywords
pyridazino
quinoline
preparation
oxide derivatives
glycine antagonists
Prior art date
Application number
CZ99201A
Other languages
English (en)
Other versions
CZ289293B6 (cs
Inventor
Wojciech Danysz
Markus Gold
Ivars Kalvinsh
Christopher Graham Raphael Parsons
Irene Piskunova
Eugene Rozhkov
Original Assignee
Merz + Co. Gmbh & Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz + Co. Gmbh & Co. filed Critical Merz + Co. Gmbh & Co.
Publication of CZ2019997A3 publication Critical patent/CZ2019997A3/cs
Publication of CZ289293B6 publication Critical patent/CZ289293B6/cs

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41661,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CZ1999201A 1996-07-25 1997-07-25 Pyridylftalazindiony, způsob jejich přípravy a pouľití a farmaceutické prostředky na jejich bázi CZ289293B6 (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/686,346 US5776935A (en) 1996-07-25 1996-07-25 Pyrido-phtalazin diones and their use against neurological disorders associated with excitotoxicity and malfunctioning of glutamatergic neurotransmission

Publications (2)

Publication Number Publication Date
CZ2019997A3 true CZ2019997A3 (cs) 1999-09-15
CZ289293B6 CZ289293B6 (cs) 2001-12-12

Family

ID=24755940

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ1999201A CZ289293B6 (cs) 1996-07-25 1997-07-25 Pyridylftalazindiony, způsob jejich přípravy a pouľití a farmaceutické prostředky na jejich bázi

Country Status (30)

Country Link
US (1) US5776935A (cs)
EP (1) EP0931081B1 (cs)
JP (1) JP3595342B2 (cs)
KR (1) KR100598206B1 (cs)
CN (1) CN1093860C (cs)
AR (1) AR004158A1 (cs)
AT (1) ATE224894T1 (cs)
AU (1) AU719993B2 (cs)
BR (1) BR9710569A (cs)
CA (1) CA2261923C (cs)
CZ (1) CZ289293B6 (cs)
DE (1) DE69715893T2 (cs)
DK (1) DK0931081T3 (cs)
EA (1) EA001711B1 (cs)
ES (1) ES2180041T3 (cs)
FI (1) FI112946B (cs)
GE (1) GEP20022801B (cs)
HU (1) HU223780B1 (cs)
IL (1) IL128225A (cs)
LT (1) LT4591B (cs)
LV (1) LV12260B (cs)
NO (1) NO310820B1 (cs)
PL (1) PL189572B1 (cs)
PT (1) PT931081E (cs)
SI (1) SI9720048B (cs)
SK (1) SK283536B6 (cs)
TW (1) TW402605B (cs)
UA (1) UA63911C2 (cs)
WO (1) WO1998004556A1 (cs)
ZA (1) ZA976612B (cs)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030176435A1 (en) * 2002-12-17 2003-09-18 Brown Dean Gordon Compounds and methods for the treatment of pain
US6444702B1 (en) 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents
CA2457011C (en) * 2001-08-20 2012-04-24 Maiken Nedergaard Treatment of glial tumors with glutamate antagonists
EP1298581A1 (fr) * 2001-09-27 2003-04-02 C.S.E.M. Centre Suisse D'electronique Et De Microtechnique Sa Procédé et dispositif pour calculer les valeurs des neurones d'un réseau neuronal
US20050069596A1 (en) * 2001-10-03 2005-03-31 Gow Robert T. Compositions and methods comprising kava and anti-anxiety compounds
US7001620B2 (en) 2001-10-03 2006-02-21 Herbal Science, Llc Kavalactone product
US7037524B2 (en) * 2001-10-03 2006-05-02 Herbalscience, Llc Oral delivery of a botanical
US7029707B2 (en) * 2001-10-03 2006-04-18 Herbalscience, Llc Method of producing a processed kava product having an altered kavalactone distribution and processed kava products produced using the same
US7291352B2 (en) 2001-10-03 2007-11-06 Herbalscience Llc Methods and compositions for oral delivery of Areca and mate' or theobromine
US7105185B2 (en) 2001-10-03 2006-09-12 Herbalscience, Llc Kavalactone profile
US20050037025A1 (en) * 2002-10-03 2005-02-17 Gow Robert T. Methods and compositions comprising kava and mate' or theobromine
US20040082543A1 (en) * 2002-10-29 2004-04-29 Pharmacia Corporation Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain
RU2266118C2 (ru) * 2003-10-21 2005-12-20 Общество с ограниченной ответственностью "Абидофарма" Мазь для лечения аутоиммунных заболеваний
RU2266119C2 (ru) * 2003-10-21 2005-12-20 Общество с ограниченной ответственностью "Абидофарма" Препарат для ингаляций при лечении туберкулеза
CN1917892A (zh) * 2003-10-24 2007-02-21 草本制药科学有限责任公司 包含冬青的方法和组合物
US7294353B2 (en) * 2003-10-24 2007-11-13 Herbalscience, Llc Methods and compositions comprising ilex
AU2006258217A1 (en) * 2005-04-08 2006-12-21 Abbott Laboratories Oral pharmaceutical formulations comprising fenofibric acid and/or its salts
WO2009038752A2 (en) * 2007-09-20 2009-03-26 Cortex Pharmaceuticals, Inc. 3-substituted 1,2,3-triazin-4-one's and 3-substituted 1,3-pyrimidinone's for enhancing glutamatergic synaptic responses
EP2264035A1 (en) * 2009-06-04 2010-12-22 Merz Pharma GmbH & Co. KGaA Glycine B antagonists
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
CA3067162A1 (en) 2017-06-12 2018-12-20 Glytech Llc. Treatment of depression with nmda antagonists and d2/5ht2a or selective 5ht2a antagonists
USD895157S1 (en) 2018-03-06 2020-09-01 IsoTruss Indsutries LLC Longitudinal beam
CN109912503B (zh) * 2019-04-01 2022-04-08 江南大学 一种2,3-二酰基喹啉类化合物的合成方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9208511D0 (en) * 1991-05-09 1992-06-03 Ici Plc Compounds
US5597922A (en) * 1994-07-29 1997-01-28 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Glycine receptor antagonist pharmacophore

Also Published As

Publication number Publication date
US5776935A (en) 1998-07-07
DK0931081T3 (da) 2003-01-27
TW402605B (en) 2000-08-21
JP2000515872A (ja) 2000-11-28
LT4591B (lt) 1999-12-27
EA001711B1 (ru) 2001-06-25
GEP20022801B (en) 2002-09-25
SI9720048B (sl) 2002-02-28
IL128225A (en) 2005-09-25
FI990134A0 (fi) 1999-01-25
CZ289293B6 (cs) 2001-12-12
HUP9903104A2 (hu) 2000-03-28
CA2261923A1 (en) 1998-02-05
NO990306L (no) 1999-03-15
NO310820B1 (no) 2001-09-03
LV12260A (lv) 1999-04-20
AU4296997A (en) 1998-02-20
CN1228778A (zh) 1999-09-15
PL189572B1 (pl) 2005-08-31
DE69715893T2 (de) 2003-01-30
BR9710569A (pt) 1999-08-17
EA199900161A1 (ru) 1999-10-28
JP3595342B2 (ja) 2004-12-02
PT931081E (pt) 2003-02-28
UA63911C2 (uk) 2004-02-16
KR20000029568A (ko) 2000-05-25
CN1093860C (zh) 2002-11-06
SK283536B6 (sk) 2003-09-11
NO990306D0 (no) 1999-01-22
LT99007A (lt) 1999-07-26
WO1998004556A1 (en) 1998-02-05
HU223780B1 (hu) 2005-01-28
EP0931081A1 (en) 1999-07-28
HK1020193A1 (en) 2000-03-31
FI112946B (fi) 2004-02-13
PL331323A1 (en) 1999-07-05
KR100598206B1 (ko) 2006-07-07
DE69715893D1 (de) 2002-10-31
ZA976612B (en) 1998-02-10
ATE224894T1 (de) 2002-10-15
CA2261923C (en) 2006-01-24
EP0931081B1 (en) 2002-09-25
LV12260B (en) 1999-08-20
SK10399A3 (en) 2000-01-18
FI990134L (fi) 1999-03-24
SI9720048A (sl) 1999-12-31
AU719993B2 (en) 2000-05-18
ES2180041T3 (es) 2003-02-01
HUP9903104A3 (en) 2000-04-28
IL128225A0 (en) 1999-11-30
AR004158A1 (es) 1998-11-04

Similar Documents

Publication Publication Date Title
CZ2019997A3 (cs) Deriváty pyridazino [4,5-B] chinolin-5-oxidu, způsob jejich přípravy a jejich použití jako antagonistů glycinu
IL129502A0 (en) Naphthyridine derivatives
FI951468A7 (fi) Lipopeptidijohdannaiset, menetelmä niiden valmistamiseksi ja niiden käyttö
FI924054A7 (fi) Imidatsoliin liitetyt iso- ja heterosyklit, menetelmä niiden valmistamiseksi ja niiden käyttö
NZ286256A (en) (hetero) arylalkylsubstituted naphthyridine and pyrido fused oxazacyclic derivatives
GB9623908D0 (en) Amino acid derivatives
IS4570A (is) Imidazó[1,2-a]pýridín afleiður
DE69800896D1 (de) 8-substituierte-1,3,8-Triazaspiro[4,5]decan-4-onderivate
AU3953097A (en) 4,5-diaminopyrimidine derivatives and a method for the preparation thereof
HUP9901630A3 (en) Indole-2,3-dione-3-oxime derivatives as antagonists of excitatory amino acids, preparation and use thereof
EE9900155A (et) 1H-pürido[3,4-b]indool-4-karboksamiidi derivaadid, nende valmistamismeetod ja kasutamine raviks
DE69803653D1 (de) 1,3,8-Triazaspiro[4,5]decan-4-on-derivate
HUP0102936A3 (en) New process for preparing n,n,6- trimethyl-2 -(4-methylphenyl)- imidazo-[1,2-a] -pyridine-3-acetamide and salts thereof
HUP0003692A3 (en) Pyrimido[4,5-b]indolyl-alkanecarboxamide derivatives
GR3035834T3 (en) Benzoxazindione derivatives, process for their preparation and their use
GB9616467D0 (en) Pyrrolo[3,2-c]quinoline derivatives
ZA9811642B (en) Pyrido 1,2,4-thiadiazine derivatives their preparation and use
DE69515498D1 (de) Naphthyridinderivate
ZA957309B (en) New thiazolo[3,2-a]quinoline and -naphthyridine derivatives
FI951828A7 (fi) Imidatsopyridiinijohdokset ja menetelmä niiden valmistamiseksi
FI954684L (fi) Imidobisfosforihapot, menetelmä niiden valmistamiseksi ja niiden käyttö
EE03762B1 (et) Protsess NMDA antagonistide valmistamiseks
HUP9701216A3 (en) New nitropyrazolester derivatives, process for their preparation and their use
ZA974108B (en) Antipicornaviral compounds and methods for their use and preparation
SI0934319T1 (en) 1H-PYRIDO(3,4-b)INDOLE-4-CARBOXAMIDE DERIVATIVES, PREPARATION AND APPLICATION THEREOF IN THERAPEUTICS